STAT+: Novo Nordisk inflammation-targeting drug misses mark in heart disease study
STAT News · LC · trust 42/100
A Novo Nordisk drug missed the mark in a heart disease study, raising questions about targeting inflammation to prevent cardiovascular complications.
Read the original at STAT News →
Open in TruthVane →